STAT3 and non-small cell lung carcinoma: Recent research has shown that currently available chemotherapeutic drugs for NSCLC induce STAT3 activation [9, 15, 16], suggesting that STAT3 may play an important role in tumor resistance to prevailing chemotherapy in NSCLC.